Novel Inactivating Mutations in the FSH Receptor Cause Premature Ovarian Insufficiency with Resistant Ovary Syndrome

W. He,J. Du,X. W. Yang,W. Li,W. L. Tang,G. X. Lu,G. Lin,F. Gong,Y. Q. Tan
DOI: https://doi.org/10.1016/j.rbmo.2018.11.011
IF: 4.567
2019-01-01
Reproductive BioMedicine Online
Abstract:Research questionWhat is the genetic aetiology of three resistant ovary syndrome (ROS) pedigrees from 13 Chinese Han families with non-syndromic premature ovarian insufficiency (POI).DesignThe proband in each family was subjected to whole-exome sequencing. Bioinformatic and in-vitro functional analyses were performed for the functional characterization of the FSHR mutations.ResultsFour novel mutations, two homozygous mutations (c.419delA, c.1510C>T), and a compound heterozygous mutation (c.44G>A and deletion of exons 1 and 2) of FSHR were identified in the three non-syndromic POI-with-ROS families. Bioinformatic analysis predicted that the three novel point mutations in FSHR are deleterious and associated with POI in the three families, which was confirmed by in-vitro functional analysis, in which FSH-induced adenosine 3′,5′-cyclic monophosphate production was abolished for all receptors.ConclusionsThe three novel point mutations in FSHR were all functional inactivating mutations, and were the genetic aetiology of the three non-syndromic POI-with-ROS families. The first FSHR frameshift mutation is reported here, and the first missense mutation in the signal peptide-encoding region of FSHR to be associated with POI. Women affected by ROS should consider undergoing mutation screening for FSHR.
What problem does this paper attempt to address?